Item 2.02. Results of Operations and Financial Condition.
In connection with the press release described in Item 8.01 below, on January 6,
2022, Eiger BioPharmaceuticals, Inc. (the "Company") provided, on a preliminary
and unaudited basis, certain estimates regarding its cash, cash equivalents and
investments as of December 31, 2021. The estimate is a preliminary estimate
based on currently available information and does not present all necessary
information for a complete understanding of the Company's financial condition as
of December 31, 2021 or the Company's results of operations for the year ended
December 31, 2021.
Item 8.01. Other Events.
On January 6, 2022, the Company issued a press release titled "Eiger
BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones."
A copy of the press release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
Forward-Looking Statements
Statements in this report that are not strictly historical in nature constitute
"forward-looking statements." Such statements include, but are not limited to
the cash, cash equivalents and investments as of December 31, 2021. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors. More information about the risks the Company faces is included
under the headings "Risk Factors" in the Company's most recently filed documents
with the U.S. Securities and Exchange Commission. The Company is providing this
information as of this date and does not undertake any obligation to update any
forward-looking statements contained in this report as a result of new
information, future events or otherwise.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press release, dated January 6, 2022, titled "Eiger
BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and
Milestones."
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses